Reviewing our work in 2023 & 2024 our CEO, Malcom Lowe-Lauri, sets out the range of advisory roles AHS has provided.

"We have been busy working in health improvement and transformation, clinical strategy and service remodelling across Integrated Care Systems (ICSs) and Provider Collaboratives.This looks likely to be a demand area in 2025 as ICSs try to reconcile service quality and best clinical practice with a worsening financial position. Besides the NHS we have also been involved overseas, supporting the Federal Government in Australia as it reviews the Medicare Benefits Schedule.

We have been similarly busy advising universities on research strategies, plans for partnerships with the life sciences industry, and commercialisation and investment planning.This has drawn not only on our scientific expertise but also on our knowledge and networks in the investor and developer segments of the life sciences market. This is a difficult time for iniversities. We are delighted to have helped a strategic rethink in preparation for the next NIHR Academic Helath Sciences Centre and Biomedical Research Centre designation rounds. This is vital given the pressure on research funding in the UK and the need for universities and their NHS partners to position themselves to optimise their combined research, innovation and clinical capabilities.

We are very pleased to be advising research charities as they refresh their research and innovation strategies and in one case develop a new role as a research funder. We expect more movement in this sector as research charities look to redefine how they work with traditional research partners and look for more rapid impact on health services and population health.

Our range of clients - from governments to individual organisations - has been a great challenge which our adviser teams have met outstandingly well."